Company Overview: Knight Therapeutics Inc. (TSX: GUD) is a specialty and generic pharmaceutical company focused on the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription medicines, consumer health products, and medical devices across Canada and selected international markets. This Report covers Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendation on this one stock. 

Canada Market Round-Up

The S&P/TSX Composite Index ended last week on a strong note, gaining 1.86% to 33,073.71 and extending its positive momentum into February 13, 2026. Gains were broad-based, led by basic materials, technology, healthcare, industrials, energy, real estate, consumer cyclicals, utilities, and financials, signalling a healthy improvement in risk appetite across both cyclical and defensive sectors. Weakness in consumer non-cyclicals, however, modestly capped the overall advance. From a technical perspective, the index continues to exhibit a firm bullish structure. Prices remain comfortably above the rising trendline support and the 21-period SMA, reinforcing the prevailing uptrend and suggesting sustained buying interest on pullbacks. Immediate resistance is seen near 33,600, where a decisive breakout could unlock further upside. On the downside, key support lies around 32,400; a sustained break below this level could trigger a short-term corrective pullback. The weekly RSI at 70.86 highlights strong momentum, though overbought conditions suggest the potential for near-term consolidation or profit-taking before the next leg higher.

On the macro front, the upcoming major economic events that may impact the Canadian market sentiment include CA CPI m/m, US FOMC Meeting Minutes and US Unemployment Claims.

Past performance is not a reliable indicator of future performance.